How profitable is Chemomab Therapeutics Ltd. (CMMB)?

In FY 2025 (10-K), CMMB converted $313.6M of revenue into a 52% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Stock Ratings / Health Care / CMMB / financials

BFRG (32) PTN (35) LTRN (31) BLRX (46) ⌘ Pro Terminal →

Chemomab Therapeutics Ltd. (CMMB) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$1.18 +1.72% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.18

Chemomab Therapeutics Ltd. (CMMB) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $9.3M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CMMB Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is CMMB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Chemomab Therapeutics Ltd. (NASDAQ: CMMB) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $1.18 (+1.72% 1D, market cap $9.3M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, CMMB ranks #778 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does CMMB compare to BFRG and PTN in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CMMB carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, BFRG (Bullfrog AI Holdings Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $9.0M) and PTN (Palatin Technologies Inc.) posts a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $8.9M). Among the 5-stock peer group, CMMB leads on earnings multiple (N/A) while CMMB leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CMMB?

▼

Per CMMB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001534248), Chemomab Therapeutics Ltd. generated $313.6M in revenue (+8.7% YoY), -$9.0M in net income, and -$11.1M in free cash flow against $13.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.18 (+0.12%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (31/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.4% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-11.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CMMB)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (31/100 Composite)

🔍 WHY CMMB SCORES 31/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (32% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Macro Regime Fit+8/20 pts (26% of score)

FRED Regime × Technicals: 12% of 52W Range • RSI-14 at 38.7 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$1.24-4.8% Next Q

Q2 (-2Q)

Grade E$1.18-11% Next Q

Q3 (-1Q)

Grade E$1.05+12.4% Next Q

Current

Grade E$1.18-9.4% Hist 90D α

Trajectory: E (39) → E (31)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CMMB Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CMMB currently carries a cautious 31/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.86) and Max Pain ($1.24) forces dealer call-delta covering toward $3.22.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CMMB• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “CMMB Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 31%NO 69%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How CMMB Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $109.0M

FY24

Rev $288.4M

FY25

Rev $313.6M

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$313.6M	52%	-35.7%	-$9.0M	-$11.1M	-45%
FY 2024	$288.4M	52%	-35.7%	-$13.9M	-$15.4M	-45%
FY 2023	$109.0M	46.7%	0%	-$24.2M	-$23.6M	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CMMB)

✓Walkthrough of CMMB's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CMMB // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -27.16%📐 HORIZONTAL RANGE

2026-11-03O $1.09H $1.18L $1.09C $1.18VOL 224.8K

RES: $3.19SUP: $0.89SMA50: $1.86SMA200: $1.75

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CMMB Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CMMB Butterfly Map → + Track CMMB →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. +8.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on CMMB today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CMMB. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CMMB today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CMMB)

Health Care Rank #778 of 1015 ⚔️ BFRG vs CMMB Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CMMB vs. BFRG, PTN, LTRN, BLRX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Chemomab Therapeutics Ltd. (CMMB) ranks #778 by composite RQD confidence (31/100, grade E) and #897 by equity capitalization ($9.3M). Within this direct 5-issuer industry benchmark cohort, CMMB leads on earnings valuation at N/A trailing P/E, while CMMB leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. BLRX currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with CMMB at 31/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CMMB ACTIVE Chemomab Therapeutics Ltd.	E	31/100	—	—	-35.0%	+1.72%	$9.3M	Benchmark Subject
BFRG Bullfrog AI Holdings Inc.	E	32/100	—	18.8%	-35.0%	+1.78%	$9.0M	/bfrg-vs-cmmb →
PTN Palatin Technologies Inc.	D-	35/100	—	—	-35.0%	-0.20%	$8.9M	/ptn-vs-cmmb →
LTRN Lantern Pharma Inc.	E	31/100	—	—	-35.0%	-3.15%	$9.9M	/ltrn-vs-cmmb →
BLRX BioLineRx Ltd.	D	46/100	—	—	—	-1.51%	$9.9M	/blrx-vs-cmmb →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001534248 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Chemomab Therapeutics Ltd. (CMMB) reported GAAP revenue of $313.6M (+8.7% vs. FY2024 revenue of $288.4M , and +187.7% cumulative change since FY2023) , GAAP net income of -$9.0M, operating cash flow of -$11.1M, and free cash flow of -$11.1M (+27.6% YoY). On the balance sheet, CMMB closed FY2025 with $13.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$313.6M	-$9.0M	-$11.1M	-$11.1M	$13.8M	—
FY2024 (FY)	2024-12-31	$288.4M	-$13.9M	-$15.4M	-$15.4M	$17.0M	—
FY2023 (FY)	2023-12-31	$109.0M	-$24.2M	-$23.6M	-$23.6M	—	—

3. CMMB Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CMMB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does CMMB compare to BFRG and PTN in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for CMMB?

Where is CMMB trading relative to its 50-day, 200-day, and 52-week technical levels?

CMMB last traded at $1.18 (+1.72% on volume of 76,443 shares), positioning the stock -36.56% below its 50-day simple moving average ($1.86) and -32.57% below its 200-day simple moving average ($1.75). Across its 52-week range of $0.92 to $3.07, CMMB sits at the 12.1% percentile with a 14-day RSI of 38.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.03 to $1.33).

Direct Sub-Reports: CMMB RQD Cockpit CMMB 12M Forecast CMMB Earnings & Move CMMB Dividends & DRIP CMMB Insiders & 13F CMMB Whale Options CMMB Profit Sankey CMMB News & Why

ROARABLE RATING BRIEF • RQD 31/100 (E) ✓ SEC XBRL & RQD VERIFIED

CMMB — Chemomab Therapeutics Ltd.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Chemomab Therapeutics Ltd. (CMMB) earns a live Roarable RQD composite score of 31/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $1.18 (+1.72% 1D, market capitalization $9.3M).

Fundamental Cash Engine (5/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
Whale 13F & Options Flow (3/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (8/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Chemomab Therapeutics Ltd. Is a NASDAQ-listed issuer classified in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry..0B in that section. — for product lines, customers, or revenue model; the financials report — revenue across the reported periods.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Chemomab Therapeutics Ltd. (CMMB) reported $313.6M in annual revenue (up from $288.4M in FY2024, +8.7% YoY) and -$9.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($109.0M revenue, -$24.2M net income) through FY2025, CMMB scaled operating cash flow to -$11.1M and free cash flow to -$11.1M, backed by $13.8M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (E • RQD 31/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 5/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $0.92 – $3.07 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies are therefore — Sector correlations beyond the stated Health Care sector and beta of 1.0 are — The principal second-order variable visible in the data is the pending merger: if the vote and financing proceed, the capital structure and share count could change materially relative to the $8.8M market capitalization shown here; this is an inference about implications rather than a sourced figure.

Key Question #1: Can CMMB sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $313.6M and free cash flow of -$11.1M, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is CMMB's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

CMMB Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Chemomab Therapeutics Ltd. (CMMB) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to CMMB Debate Forum (3) ↓

🟡 MARKET WIRE Stock Titan • 22h ago

A vote on the proposed merger is set for Dec. 4. Chemomab shareholders will weigh the deal.

Stock Titan report covering Chemomab Therapeutics Ltd. (CMMB) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago

Bolt Biotherapeutics, Inc. (BOLT) Seasonal Returns Chart - Yahoo Finance

Yahoo! Finance Canada report covering Chemomab Therapeutics Ltd. (CMMB) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

Chemomab Therapeutics Ltd. SEC Filing (Nov 2, 2026)

Stock Titan report covering Chemomab Therapeutics Ltd. (CMMB) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance UK • 1d ago

Bolt Biotherapeutics, Inc. (BOLT) Seasonal returns chart

Yahoo Finance UK report covering Chemomab Therapeutics Ltd. (CMMB) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

$10M already counts toward the financing required for Chemomab (CMMB)'s proposed Scipher merger.

Stock Titan report covering Chemomab Therapeutics Ltd. (CMMB) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago

HCW Biologics Inc. (HCWB) Seasonal Returns Chart - Yahoo Finance

Yahoo! Finance Canada report covering Chemomab Therapeutics Ltd. (CMMB) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Yahoo • 1d ago

Chemomab Therapeutics and Scipher Medicine Announce SEC Registration Statement on Form S-4 Is Effective

Special meeting of Chemomab shareholders to vote on the proposed merger scheduled for December 4, 2026 TEL AVIV, Israel, and DURHAM, N.C., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Chemomab Therapeutics (Nasdaq: CMMB) (“Chemomab

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

CMMB Bull vs. Bear Conversation Board — What's Your Call at $1.18?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CMMB 🐻 33% BEARISH CONVICTION

AL AlphaFlow_Cap RQD DEBATE OPENER • Verified $100K Arena Trader 🐂 BULLISH 🎯 Target: $1.36 (+17.2%)

📌 Pinned Debate

Forensic balance-sheet pillar scores 10/20 with reported cash of $7.6M and Debt/Equity of 0.5.

The street is overcomplicating Chemomab Therapeutics Ltd. (CMMB). Forensic balance-sheet pillar scores 10/20 with reported cash of $7.6M and Debt/Equity of 0.5.. With an RQD score of 31/100 (E) and Forensic Balance Sheet at 10/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $1.25.

RetailWhale_TX 🐂 BULL

Both sides have a point here — CMMB's 10/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

BE BearTrap_Alert RQD DEBATE OPENER • Cycle Peak Watcher 🐻 BEARISH 🎯 Target: $1.00 (-13.8%)

Spot @ $1.16

ROIC of -35%, zero revenue, and FCF yield of 0% leave no cash-flow support for the $1.09 price.

ROIC of -35%, zero revenue, and FCF yield of 0% leave no cash-flow support for the $1.09 price.. Look at the math on CMMB: paying current EV/EBITDA multiples for -35.0% ROIC and 0.0% operating margins leaves zero margin of safety if Biotechnology: Pharmaceutical Preparations demand softens. I'd wait for a retest of $1.02 before getting long.